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Abstract  28 
Background	29 
Central	fat	accumulation	is	important	in	Non-alcoholic	Fatty	Liver	Disease	(NAFLD)	etiology.	It	is	30 
unknown	weather	any	commonly	used	waist	circumference	(WC)	measurement	protocol	(mp),	as	whole	31 
and	central	fat	accumulation	marker,	is	preferable	for	patients	with	NAFLD.	The	present	study	sought	to	32 
find	a	preferable	WC	mp	to	be	used	in	patients	with	NAFLD,	based	on	three-fold	criterion.		33 
Material	and	methods	34 
Body	fat	(BF)	was	assessed	through	Dual	Energy	X-ray	Absorptiometry	(DXA)	in	28	patients	with	NAFLD	35 
(19	males,	51	+	13	yrs,	and	9	females,	47	+	13	yrs).	WC	was	measured	using	four	different	WC	mp	(WC1-	36 
narrowest	torso,	WC2-	just	above	iliac	crest,	WC3-	mid-distance	between	iliac	crest	and	last	rib	and	37 
WC4-	at	the	umbilicus).		38 
Results	39 
All	WC	measurements	were	highly	correlated	particularly	with	central	BF	depots,	including	trunk	BF	40 
(r=0.78;	r=0.82;	r=0.82;	r=0.84;	respectively	for	WC1,	WC2,	WC3	and	WC4)	abdominal	BF	(r=0.78;	41 
r=0.78;	r=0.80;	r=0.72;	respectively	for	WC1,	WC2,	WC3	and	WC4)	and	central	abdominal	BF	(r=0.76;	42 
r=0.77;	r=0.78;	r=0.68;	respectively	for	WC1,	WC2,	WC3	and	WC4),	controlling	for	age,	sex	and	body	43 
mass	index.	There	were	no	differences	between	the	correlation	coefficients	obtained	between	all	44 
studied	WC	measurements	and	each	whole	and	central	analyzed	BF	variable.		45 
Conclusion	46 
All	studied	WC	mp	seem	suitable	for	use	in	patients	with	NAFLD,	particularly	as	central	BF	clinical	47 
assessment	tool,	though	not	interchangeably.	Hence	biological	and	precision	criteria	alone	did	not	48 
sanction	the	superiority	of	any	WC	mp.	Practical	criteria	may	endorse	WC	measured	at	the	iliac	crest.	49 
	50 
51 
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Introduction  52 
Non-Alcoholic	 Fatty	 Liver	 Disease	 (NAFLD)	 is	 a	 rising	 recognized	 condition	 that	 has	53 
caught	growing	attention.	In	an	advanced	stage	NAFLD	can	ultimately	lead	to	advanced	fibrosis,	54 
cirrhosis,	 liver	 failure	 and	 death	 1,2.	 NAFLD	 is	 also	 associated	 with	 increased	 risk	 of	55 
cardiovascular	events	 3.	Both	central	body	 fat	 (BF)	and	 insulin	 resistance	have	been	 found	 to	56 
increase	the	risk	of	NAFLD	4,	 furthermore	whole	and	particularly	central	BF	may	also	 increase	57 
the	 risk	 for	NAFLD	by	 its	 strong	association	with	 insulin	 resistance	 5,6.	Excess	both	whole	and	58 
central	BF	accumulation	is	also	a	known	cardiovascular	risk	factor	7,8.	These	evidences	arise	the	59 
importance,	particularly	 in	 this	higher	 risk	 sub-population,	of	 finding	 risk	 related	clinical	body	60 
composition	surrogates,	and	potential	therapy	targets.		61 
Waist	 circumference	 (WC)	 measurement	 is	 widely	 used	 in	 different	 settings	 and	62 
populations	 9–11,	 including	 the	 sub-population	 of	 patients	 with	 NAFLD	 12.	 WC	 has	 been	63 
considered	 a	 proper	 surrogate	 of	 body	 composition,	 particularly	 when	 focusing	 on	 body	 fat	64 
distribution	9,13,14,	and	a	risk	factor	for	NAFLD	15.	In	patients	with	NAFLD	WC	has	been	found	to	65 
be	associated	with	several	metabolic	impairments	including	insulin	resistance	5,16	as	well	as	liver	66 
fat	 12	 and	 NAFLD	 severity	 17.	 Even	 though	 widely	 used,	 there	 is	 currently	 no	 optimal	 and	67 
uniquely	proposed	WC	measurement	protocol	(WCmp)	to	be	used	in	clinical	practice,	either	in	68 
the	 general	 population	 as	 in	 specific	 higher	 risk	 sub-populations.	 Several	 WCmp	 have	 been	69 
suggested	but	 scientific	 rational	 is	 lacking	 to	 recommend	one	 single	protocol	 10,18.	 Suggested	70 
protocols	differ	mainly	on	 the	anatomical	 landmarks	and	correspondent	measuring	sites.	The	71 
most	commonly	used	WC	measurement	sites	are	the	midpoint	between	the	lowest	rib	and	iliac	72 
crest,	the	umbilicus	and	the	minimal	waist,	still	a	fourth	measurement	site	has	also	been	used	73 
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and	endorsed,	which	is	at	the	superior	border	of	the	iliac	crest	9,10.	Nevertheless	several	other	74 
measuring	sites	have	been	sparsely	used	10.					75 
To	our	knowledge	 this	 is	 the	 first	 study	 to	 look	 into	 the	usefulness	of	commonly	used	76 
waist	 circumference	 measurements	 as	 surrogates	 of	 whole	 and	 central	 body	 fat	 content	 in	77 
patients	with	NAFLD.	 Therefore	 the	 aim	of	 the	 present	 study	was	 to	 find	which	 of	 the	most	78 
used	 WCmp	 is	 the	 best	 for	 use	 in	 clinical	 practice	 in	 patients	 with	 NAFLD,	 considering	 a	79 
threefold	criteria:	the	WC	most	closely	associated	with	whole	and	central	BF	content	in	patients	80 
with	NAFLD;	the	most	precise	WCmp;	the	most	practical	WCmp	to	use	in	clinical	practice.		81 
Materials and methods 82 
Subjects:		83 
This	 study	was	 conducted	 at	 Exercise	 and	Health	 Laboratory,	 from	 the	 Interdisciplinary	84 
Centre	for	the	Study	of	Human	Performance	(Faculty	of	Human	Kinetics,	Technical	University	of	85 
Lisbon,	Portugal).	To	be	selected	for	the	present	study	subjects	had	to	be	over	18	years	of	age,	86 
diagnosed	 with	 NAFLD,	 without	 history	 of hepatotoxic	 substances	 intake	 (eg.	 steroids)	 and	87 
tobacco	 consumption.	 Exclusion	 criteria	 included	 alcohol	 consumption	 over	 20	 gr/day;	 the	88 
presence	 of	 other	 possible	 causes	 for	 fatty	 liver	 disease,	 including	 hepatitis,	 self-immune	89 
disease	and	others;	any	physical	and/or	mental	disabilities	or	any	condition	that	constituted	an	90 
absolute	 restriction	 from	 exercise,	 or	 diseases,	 other	 than	 metabolic	 (insulin	 resistance,	91 
hypertension	or	dyslipidemia),	with	mandatory	specific	pharmacologic	therapy	(eg.	Asthma	or	92 
other).	We	studied	28	patients	with	NAFLD	(19	males,	51	+	13	yrs,	and	9	females,	47	+	13	yrs)	93 
who	 were	 diagnosed	 through	 liver	 biopsy	 or	 ultrasound.	 Subjects	 were	 recruited	 from	 the	94 
outpatient	periodical	medical	consultations	in	Santa	Maria	Hospital	and	Curry	Cabral	Hospital;	95 
59	consecutive	patients	were	selected	based	on	selection	criteria;	37	of	the	selected	subjects	96 
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accepted	 to	participate	and	28	were	 found	eligible	 to	enter	 the	 study	after	exclusion	 criteria	97 
was	 considered.	 Subjects	 were	 taking	 one	 or	 more	 of	 the	 following	 medication:	 platelet	98 
inhibitors,	angiotensin-converting	enzyme	inhibitors,	nitrates,	statins,	ezetimibe,	nicotinic	acid	99 
and	 biguanides	 with	 similar	 use	 among	 both	 genders.	 All	 participants	 signed	 an	 informed	100 
consent	before	being	 included	 in	 the	present	 study	and	undergoing	any	 study	procedure.	All	101 
methods	used	 in	the	present	study	complied	with	good	ethics	and	Portuguese	 laws	and	were	102 
approved	 by	 both	 the	 Portuguese	 Foundation	 for	 Science	 and	 Technology	 and	 Faculty	 of	103 
Human	Kinetics	institutional	review	boards.				104 
Body	composition:		105 
Body	composition	was	assessed	using	Dual	Energy	X-ray	Absorptiometry	(DXA)	(Explorer	106 
W,	 Hologic;	 Waltham,	 MA,	 USA;	 Fan	 bean	 mode)	 whole	 body	 scans	 and	 anthropometric	107 
measurements.	Repeated	measurements	 in	18	young	adults	showed	a	coefficient	of	variation	108 
(CV)	of	1.7%	for	total	BF	mass	and	1.5%	for	total	%BF.	All	scans	were	made	in	the	morning	after	109 
an	overnight	12-hour	 fast.	Quality	control	with	spine	phantom	was	made	every	morning,	and	110 
with	 step	 phantom	 every	 week.	 By	 default	 DXA	 software	 (QDR	 for	 windows,	 version	 12.4)	111 
estimates	the	head,	trunk,	arms	and	legs,	both	left	and	right,	regions	fat	content,	according	to	a	112 
three-compartment	model	 (fat	mass,	 lean	 tissue	 and	 bone	mass).	Whole	 BF,	 sometimes	 just	113 
referred	 to	 as	BF,	 includes	 the	 fat	mass	 of	 the	whole	body,	 as	 opposed	 to	 central	 BF,	which	114 
refers	 to	 the	trunk	BF,	abdominal	BF	and	central	abdominal	BF	variables,	as	analyzed	by	DXA	115 
regions	of	interest.	The	trunk	region	of	interest	(ROI)	(CV	=	0.5%)	includes	chest,	abdomen	and	116 
pelvis,	to	provide	estimates	of	trunk	BF	and	trunk	%BF.	All	scans	were	submitted	to	additional	117 
analysis	by	ROI	to	assess	absolute	a	relative	fat	content	of	the	abdominal	(Abd	BF	and	Abd	%BF)	118 
and	central	abdominal	 regions	 (CAbd	BF	and	CAbd	%BF)	 (Fig.	1)	 (CV	=	1.0	%).	The	upper	and	119 
lower	limits	of	the	abdominal	and	central	abdominal	ROI	were	determined	as	the	upper	edge	of	120 
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the	second	lumbar	vertebra	to	the	lower	edge	of	the	fourth	lumbar	vertebra,	respectively	19–21.	121 
The	 sides’	 limits	 of	 the	 abdominal	 ROI	 were	 determined	 as	 to	 include	 all	 trunk	 length,	 but	122 
exclude	any	upper	limb	scan	area	20,21,	whereas	the	vertical	sides	of	central	abdominal	ROI	were	123 
the	continuation	of	the	lateral	sides	of	the	ribs	cage,	as	to	exclude	the	lateral	subcutaneous	fat	124 
of	 the	 trunk,	 including	 the	anterior	and	posterior	 subcutaneous	abdominal	 fat,	as	well	as	 the	125 
intra-abdominal	 fat	 19,	 as	 seen	 in	 figure	 1.	 Absolute	 and	 relative	 BF	 content	 results	 were	126 
registered	to	the	nearest	0.01kg	and	0.1%,	respectively.	127 
Anthropometric	measurements	consisted	of	weight,	height	and	body	mass	index	(BMI)	128 
as	 well	 as	 WC.	 Some	 standardization	 procedures	 were	 taken	 into	 account,	 as	 proposed	 by	129 
Agarwal	 and	 colleagues	 22	 to	 avoid	 any	 bias	 in	 the	 measurements,	 therefore	 all	 WC	130 
measurements	were	made	with	subjects	in	a	standing	comfortable	position,	in	their	underwear,	131 
in	a	12-hour	fasting	state.	All	WC	measurements	were	made	by	the	same	technician,	who	was	a	132 
trained	 level	 2	 technician,	 certified	 by	 the	 International	 Society	 for	 the	 Advancement	 of	133 
Kinanthropometry,	 using	 an	 inelastic	 flexible	 metallic	 tape	 (Lufkin	 -	 W606PM,	 Vancouver,	134 
Canada)	 parallel	 to	 the	 floor	 after	 a	 tidal	 expiration,	 to	 the	 nearest	 0.1cm.	 The	 WC	135 
measurement	 sites	 in	 the	 present	 study	 were	 the	 narrowest	 torso	 (WC1)	 23,24,	 also	 called	136 
minimal	waist10,	superior	border	of	the	iliac	crest	(WC2)	18,25,	midpoint	(WC3)	26	and	umbilicus	137 
(WC4)	27,28,	as	detailed	 in	table	1,	and	represented	 in	figure	2.	These	are	the	most	commonly	138 
used	 protocols	 endorsed	 by	 sound	 authorities	 in	 this	 field	 9,10.	 Time	 length	 of	 each	 WC	139 
measurement,	 including	 all	 procedures,	 from	 brief	 initial	 instruction	 results	 registering,	 was	140 
recorded	 in	 seconds,	 to	 the	 nearest	 1	 second,	 with	 a	 standard	 watch	 chronometer	 (model	141 
RS800,	Polar,	Oulu,	Finland).	Body	weight	was	measured	to	the	nearest	0.1kg,	and	height	was	142 
measured	 to	 the	nearest	0.1	 cm,	on	a	 scale	with	an	attached	 stadiometer	 (model	770,	 Seca;	143 
Hamburg,	Deutschland),	according	to	standard	protocol	23.	Both	weight	and	height	were	used	144 
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to	calculate	the	subjects’	BMI,	by	dividing	the	weight,	 in	kg,	by	the	squared	height,	 in	meters	145 
(BMI	=	weight	[kg]	/	height	[m]2).	All	anthropometric	measurements	were	repeated	two	times,	146 
and	 if	 the	second	differed	more	 than	1cm	(for	waist	and	height	measurements)	or	0,5kg	 (for	147 
weight	measurement)	from	the	first	measurement,	a	third	measurement	was	carried	out.	We	148 
always	considered	the	result	obtained	in	the	second	measurement	unless	a	third	measurement	149 
was	carried	out.	When	a	 third	measurement	was	 taken	we	considered	 the	mode	or,	 if	mode	150 
was	absent,	the	median	value	of	all	three	measurements.	By	using	this	procedure	we	sought	to	151 
always	 use	 the	 most	 suitable	 value	 that	 was	 actually	 measured	 on	 the	 subjects	 (instead	 of	152 
mean	values).		153 
Statistical	methods:		154 
Descriptive	 statistics	 are	presented	as	mean	±	 sd	and	 range	 for	all	 analyzed	variables.	155 
The	Gaussian	distribution	of	the	data	was	assessed	with	the	Shapiro-Wilk	goodness-of-fit	test.	156 
Levenne	test	was	used	for	assessing	sample	variance	homogeneity.		Paired-samples	T	test	was	157 
used	 to	 compare	WC	 results	 obtained	with	 different	WCmp.	When	homogeneity	 of	 variance	158 
was	not	present,	the	corrected	significance	values	of	T	test	were	used.	The	association	between	159 
whole	and	central	BF	and	the	results	obtained	with	each	WCmp	was	assessed	using	partial	as	160 
well	as	part,	also	called	semipartial	29,	correlations,	controlling	for	age	and	sex	and	BMI.	Both	161 
partial	 and	 semipartial	 correlation	 techniques	 allow	 controlling	 for	 confounders	 but,	 while	162 
partial	 correlation	 remove	 from	 the	 analysis	 the	 confounders-related	 variation	 of	 both	163 
dependent	 and	 independent	 variables,	 the	 semipartial	 technique	 only	 removes	 from	 the	164 
correlation	analysis	the	confounder-related	variation	of	the	independent	variable	29.	In	order	to	165 
accomplish	 a	 statistical	 power	 of	 80%	 (β	 =	 0.20)	 at	 a	 statistical	 significance	 level	 of	 5%	 (α	 =	166 
0.05),	only	coefficients	of	correlation	equal	or	superior	to	0.5,	corresponding	to	a	 large	effect	167 
size,	were	considered	significant.	This	is	in	accordance	with	Cohen	and	Cohen	29	to	assure	that	168 
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results	 are	 unexposed	 to	 type	 I	 and	 II	 errors,	 despite	 an	 rather	modest	 sample	 size.	 Pairs	 of	169 
correlation	 coefficients	 obtained	 between	 each	 WC	 with	 each	 dependent	 variable	 were	170 
compared,	 using	 Z	 statistic,	 to	 find	 if	 any	WC	 was	 more	 closely	 associated	 with	 whole	 and	171 
central	 BF.	 To	 evaluate	 the	 precision	 of	 the	 studied	 WCmp	 we	 calculated	 coefficients	 of	172 
variation	 for	 the	repeated	measurements,	and	compared	them	between	WCmp	using	paired-173 
samples	 T	 test.	 To	 respond	 to	 the	 third	 criteria,	 comprised	 in	 the	 aim	 of	 the	 present	 study,	174 
paired-samples	 T	 test	 was	 used	 to	 compare	 the	 time	 consumption	 of	 WC	 measurement	175 
between	 different	measurement	 protocols.	 Statistical	 calculations	were	 performed	 using	 the	176 
IBM	SPSS	Statistics	version	19	(SPSS,	inc,	Chicago,	IL),	except	for	z	statistic	which	was	performed	177 
using	Medcalc	version	11.1.1.0	(MedCalc	Software,	Mariakerke,	Belgium).	178 
Results  179 
Mean	 values	 for	 all	 studied	 variables	 are	 presented	 in	 table	 2.	 From	 among	 the	 28	180 
studied	patients	with	NAFLD	obesity	was	present	 in	9	 subjects	 (3	were	 female),	 according	 to	181 
BMI	 classification,	 yet	 mean	 BMI	 showed	 no	 differences	 between	 sexes	 (p=0.075	 on	182 
independent	samples	t	test)	and	was	considered	to	be	in	the	overweight	category	for	the	whole	183 
studied	 sample.	 BMI	was	 also	 not	 related	with	 subjects’	 age	 (r=	 -0.222;	 p=0.266	 on	 Pearson	184 
correlation).	Results	for	WC	measurements	were	considered	to	be	different	between	all	studied	185 
WCmp,	 for	 instance	WC4	 showed	 the	 highest	 values	 whereas	WC1	 showed	 the	 lowest,	 and	186 
WC3	was	smaller	than	WC2,	as	shown	in	table	3.			187 
Table	4	shows	the	results	for	partial	and	semipartial	correlations	between	each	WC	and	188 
each	whole	or	central	 studied	BF	depot	controlled	 for	 sex,	age	and	BMI.	All	WC	results	were	189 
somewhat	correlated	with	the	overall	studied	DXA	assessed	BF	depots,	controlling	for	age,	sex	190 
and	 BMI,	 often	 showing	 correlation	 coefficients	 above	 0.5.	 WC4	 was	 correlated	 with	 both	191 
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absolute	 and	 relative	 whole	 BF,	 while	 WC1,	 WC2	 and	 WC3	 were	 correlated	 only	 with	 the	192 
absolute	 values	of	whole	BF,	 but	 only	 in	 partial	 correlations.	All	 studied	WC	were	 correlated	193 
with	absolute	and	relative	trunk	BF,	in	partial	correlations,	however,	in	semipartial	correlations,	194 
this	was	 true	only	 for	 the	absolute	values	of	 trunk	BF.	WC	1,	WC2	and	WC3	were	associated	195 
with	 absolute	 a	 relative	 values	 of	 abdominal	 fat	 depots,	 except	 for	 WC4	 which	 was	 only	196 
correlated	 with	 Abd	 BF	 and	 Cabd	 BF,	 in	 partial	 correlations.	 Semipartial	 correlations	 only	197 
confirmed	the	correlation	with	Abd	BF	and	CAbd	BF,	for	all	WC.		198 
Table	5	show	the	results	for	the	comparison	between	the	correlation	coefficients	listed	199 
in	 table	4.	Comparisons	were	made	between	pairs	of	competing	WC	correlations	results	with	200 
each	dependent	variable.	No	differences	were	found	between	all	performed	correlations	with	201 
each	studied	BF	depot.		202 
Table	6	shows	both	the	coefficients	of	variation	for	the	WC	measurements	according	to	203 
the	studied	protocols,	as	well	as	the	mean±sd	time	spent	for	WC	measurements	using	each	of	204 
the	studied	WCmp.	Coefficient	of	variation	was	not	different	irrespectively	of	the	WCmp	used.	205 
Time	spent	in	each	measurement	was	longer	for	WC3	as	compared	to	all	others.	WC2	was	more	206 
time	consuming	than	both	WC1	and	WC4.	Both	of	 the	 latest	showed	no	differences	between	207 
their	mean	 time	 lengths	 of	measurements.	 In	 summary	 time	 length	 of	measurement	 of	 the	208 
studied	protocols	was	as	follows:	WC1	and	WC4	<	WC	2	<	WC3.		209 
Discussion  210 
Even	though	WC	has	been	a	widely	used	measure	in	the	sub-population	of	patients	with	211 
NAFLD	 12,30,	 to	 our	 knowledge	 this	 is	 the	 first	 study	 to	 focus	 on	 the	 comparison	 of	 different	212 
WCmp	 based	 on	 a	 scientific	 and	 practical	 rational.	 The	 prevalence	 of	 high	 levels	 of	 BMI,	213 
including	 obese	 and	 morbidly	 obese	 patients,	 in	 the	 present	 sample	 was	 expected	 since	214 
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obesity,	along	with	insulin	resistance,	have	been	identified	among	the	strongest	risk	factors	for	215 
NAFLD,	and	therefore	highly	prevalent	in	this	sub-population	31–34.	WC	results	were	also	quite	216 
high	which	was	consistent	with	BMI	levels.	The	magnitudes	of	WC	mean	values	were	different	217 
according	to	the	protocol	in	use,	as	has	been	previously	reported	in	different	populations	35–37,	218 
meaning	they	are	not	interchangeable.	This	has	imperative	implications	advising	the	consistent	219 
use	of	one	single	protocol	to	avoid	misinterpretations	either	when	monitoring	longitudinal	data	220 
as	when	using	cut-off	for	classification	of	WC	values	and	subjects	subject’s	risk	 level	appraisal	221 
35,38,39.	 Based	 on	 the	 small	 or	 absent	 differences	 reported,	 particularly	 in	 men,	 between	222 
measurements	 of	WC2	 (at	 the	 superior	 border	 of	 the	 iliac	 crest)	 and	WC3	 (at	 the	midpoint	223 
between	 lowest	 rib	 and	 iliac	 crest)	 35–37,	 it	 was	 proposed	 that	 current	 WC	 thresholds,	224 
generalized	 using	WHO	WCmp	 (WC3),	 could	 be	 applied	 to	measurements	 using	WC2	 10.	Our	225 
data	 do	 not	 support	 the	mentioned	 generalization	 for	 patients	with	NAFLD,	 yet	 this	 analysis	226 
was	 not	 in	 the	 aim	 of	 the	 present	 study,	 and	 additional	 research	 is	 needed	 to	 look	 into	 sex	227 
differences	 and	 other	 possible	 influencing	 variables.	 These	 results	 reinforce	 the	 necessity	 of	228 
searching	 for	 the	most	useful,	 consensual	and	standardized	WCmp	 for	use	 in	clinical	practice	229 
with	patients	with	NAFLD.		230 
In	the	present	sample	of	patients	with	NAFLD	WC	was	highly	associated	with	whole	and	231 
central	 BF,	 adjusted	 for	 age,	 sex	 and	 BMI.	 The	 association	 of	WC	 with	 BC,	 particularly	 with	232 
central	BF	has	long	been	reported	in	diverse	populations	40–42.	Wang	and	colleagues	(2003)	had	233 
already	found	stronger	associations	between	WC	and	absolute	central	BF,	as	opposed	to	either	234 
whole	 BF	 or	 any	 relatively	 expressed	 BF	 depot,	 assessed	 by	 DXA.	 In	 the	 present	 report,	 the	235 
results	 obtained	 in	 partial	 correlation	 may	 suggest	 that	 WC1,	 WC2	 and	 WC3	 are	 more	236 
consistently	 associated	 with	 central	 BF,	 and	 therefore	 seem	 better	 markers	 of	 a	 more	237 
hazardous	fat	accumulation	in	the	studied	sample	of	patients	with	NAFLD,	as	opposed	to	WC4	238 
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which	 seems	 more	 consistently	 associated	 with	 Whole	 BF.	 When	 the	 results	 obtained	 in	239 
semipartial	 correlations	 were	 taken	 into	 consideration,	 all	 studied	 WC	 were	 similarly	 only	240 
correlated	with	central	BF	accumulation,	namely	trunk	BF,	Abd	BF	and	CAbd	BF,	controlled	for	241 
age,	sex	and	BMI,	revealing	a	cognate	association	pattern	among	different	WCmp.	Central	BF	242 
accumulation	has	been	found	highly	important	in	NAFLD	etiology	(Park	et	al.	2007)	and	is	also	a	243 
risk	factor	for	cardiovascular	diseases	incidence	and	outcomes	7,8,	which	is	increased	in	NAFLD	244 
(Targher	et	al.	2005).	The	present	results	support	the	use	of	WC	measurement	in	patients	with	245 
NAFLD,	 as	 a	 cost-effective	 screening	 procedure,	 to	 assess	 hazardous	 body	 composition	246 
phenotypes,	namely	central	BF	accumulation,	 in	routine	clinical	appraisals,	 irrespective	of	 the	247 
WCmp	in	use.	248 
Comparisons	between	pairs	of	competing	WC	correlations	results	with	each	dependent	249 
variable	 showed	 no	 differences	 meaning	 all	 WC	 results	 are	 similarly	 associated	 with	 the	250 
analyzed	BF	depots,	 irrespectively	of	 the	WCmp	used,	 in	 the	 studied	 sample	of	patients	with	251 
NAFLD.	 Never	 the	 less,	 conflicting	 results	 can	 be	 found	 in	 general	 population	 36,37.	 A	 report	252 
focusing	 on	 different	WC	measuring	 sites,	 including	 at	 the	 superior	 border	 of	 the	 iliac	 crest	253 
(WC2)	 and	 also	 at	 the	midpoint	 between	 lowest	 rib	 and	 iliac	 crest	 (WC3),	 found	 differences	254 
between	 correlation	 coefficients,	 in	 partial	 correlations,	 with	 abdominal	 adipose	 tissue	255 
assessed	with	magnetic	resonance	imaging,	in	women	but	not	in	men	37.	In	agreement	with	the	256 
present	 report,	Wang	and	 colleagues	 36	 found	WC	 correlations	 to	be	 stronger	with	 trunk	BF,	257 
regardless	of	sex	and	WCmp.	The	present	results	showing	a	preferable	association	between	WC	258 
and	 preferably	 central	 BF,	 regardless	 of	 WCmp,	 together	 with	 the	 well-established	 recently	259 
reported	 10	 relationships	 between	WC	 and	morbidity	 of	 cardiovascular	 disease	 and	 diabetes	260 
and	 with	 cardiovascular	 and	 all-cause	 mortality,	 also	 rather	 unaffected	 the	 use	 of	 different	261 
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WCmp,	 settle	 both	 the	 importance	 of	 WC	 measurement	 in	 the	 screening	 of	 patients	 with	262 
NAFLD	as	well	as	the	usefulness	of	WC	measurement	regardless	the	WCmp	in	use.		263 
In	 the	 absence	 of	 biological	 support	 for	 the	 use	 of	 one	 preferable	WCmp,	 additional	264 
criteria	have	been	suggested	in	the	attempt	to	substantiate	the	choice	of	one	particular	WCmp,	265 
including	the	use	of	bony	landmarks	and	ease	of	measurement	9,10,18.	It	was	argued	that	the	use	266 
of	 bony	 landmarks	 could	 be	 preferable	 due	 to	 increased	 precision	 9	 or	 reliability	 10,18.	 The	267 
present	 data	 do	 not	 confirm	 better	 precision	 of	 any	 particular	 WCmp,	 as	 assessed	 by	 the	268 
comparison	 of	 coefficients	 of	 variation	 obtained	 for	 each	 WCmp.	 Similar	 results	 have	 been	269 
reported	elsewhere	in	the	general	population	35,36.	Additional	research	is	warranted	to	support	270 
or	reject	the	preferable	use	of	bony	landmarks,	particularly	for	longitudinal	assessments.	Ease	271 
of	measurement,	meaning	 that	WCmp	 should	 require	 less	 specific	 training	 and	 be	 less	 time	272 
consuming,	has	been	proposed	as	an	important	criteria	for	the	adoption	of	any	measurement	273 
by	general	public	and	practitioners	in	routine	clinical	practice	9.		274 
It	has	been	suggested	that	WC	measured	at	the	superior	border	of	the	iliac	crest	would	275 
be	more	likely	adopted	by	general	public	and	practitioners	as	it	requires	only	the	palpation	of	276 
one	 bony	 landmark	 18	 however	 this	 was	 not	 confirmed	 by	 practice	 nor	 research	 9,10.	 Bony	277 
landmarks	 have	 been	 subjectively	 reported	 to	 require	 more	 training	 and	 experience	 of	278 
observers,	yet,	 in	 the	present	study	only	 the	 lowest	 rib	 landmark	proved	demanding.	Limited	279 
time	availability	has	been	proposed	as	one	of	 the	 reasons	 for	not	using	WC	measurement	 in	280 
routine	 clinical	 practice	 9.	 Present	 data	 also	 objectively	 confirm	 a	 previous	 report	 35	 that	281 
subjectively	 pointed	WC	measurement	 at	 the	midpoint	 between	 lowest	 rib	 and	 iliac	 crest	 as	282 
more	time	consuming	than	when	using	other	studied	WCmp.		283 
There	are	several	 strengths	and	 limitations	 to	 this	 study.	The	studied	WCmp	do	not	cover	all	284 
protocols	 existent	 in	 the	 literature,	 yet	 the	 focus	 was	 set	 on	 the	most	 commonly	 used	 and	285 
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endorsed	by	prominent	institutions	for	use	in	clinical	setting	9,10,18.	Also	the	used	BC	assessment	286 
method	 (DXA),	 a	 gold	 standard	 instrument	 to	 assess	 BC	 in	 a	 three-compartment	 model,	 is	287 
unable	to	determine	visceral	adiposity	 independently	from	subcutaneous	fat.	However	strong	288 
correlation	between	abdominal	fat	estimated	from	selected	DXA	ROI	and	visceral	fat	measured	289 
directly	by	magnetic	resonance	imaging	(Park	et	al.	2002)	and	computed	tomography	43,44	have	290 
been	reported.	Due	to	the	cross-sectional	approach	used,	the	usefulness	of	the	studied	WCmp	291 
to	assess	longitudinal	changes	in	the	studied	BF	depots	could	not	be	established,	based	on	the	292 
present	results.	Finally,	the	size	of	the	sample	was	rather	constrained	due	to	difficulties	in	the	293 
recruitment	of	such	a	specific	sub-population.	90	individuals	were	coveted	to	be	included	in	the	294 
present	sample	in	the	initial	research	project.	This	would	allow	coefficients	of	correlation	as	low	295 
as	 0.3,	 traditionally	 corresponding	 a	 moderate	 effect	 size,	 to	 be	 considered	 significant	 and	296 
unexposed	 to	 type	 I	 and	 II	 errors	 29.	Unfortunately,	 despite	 all	 efforts	 on	behalf	 of	 everyone	297 
involved	 in	 this	 research	project,	only	28	patients	with	NAFLD	could	be	recruited,	meeting	all	298 
inclusion	and	exclusion	criteria.	Consequently,	only	associations	equal	or	higher	to	r=0.50	could	299 
be	considered	to	attain	minimal	statistical	power	of	80%	and	statistical	significance	of	5%,	and	300 
could	be	considered	fairly	unexposed	to	type	I	and	type	II	errors	29.	Nevertheess	the	aim	of	the	301 
present	study	was	to	find	the	preferable	WCmp	to	use	with	patients	with	NAFLD,	which	should	302 
be	 found	 at	 the	 higher	 end	 of	 correlational	 range,	 therefore,	 the	 inability	 to	 find	 significant	303 
associations	lower	than	r=0.5,	though	interesting	are	not	the	aim	of	the	present	study.		304 
The	 present	 study	 confirms	 the	 strong	 association	 between	WC	 and	 central	 BF,	 even	305 
after	 removing	 the	effect	of	age,	 sex	and	BMI,	 regardless	of	 the	WCmp	 in	use.	Moreover,	all	306 
tested	WCmp	could	be	considered	useful	and	important	low-cost	assessment	tools	for	clinical	307 
practice,	 though	 not	 interchangeable.	 This	 irrespective	 usefulness	 is	 bolstered	 by	 the	 similar	308 
precision	 found	for	all	 studied	WCmp.	On	the	other	hand	there	could	not	be	established	one	309 
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single	 preferable	WCmp	 for	 the	 present	 sample	 of	 patients	 with	 NAFLD	 based	 on	 biological	310 
criteria.	The	use	of	bony	landmarks	showed	no	superiority,	though	research	is	needed	to	assess	311 
its’	relevance	in	longitudinal	assessments.	WC	measured	at	the	superior	border	of	the	iliac	crest	312 
may	be	a	good	choice	if	a	bony	landmark	is	valued	together	with	time	consuming.		313 
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TABLES:	439 
Table	1.	Circumferences	measurement	protocols	and	references.	440 
Measurement	 Protocol	 References	
WC	1	 Measured	at	the	level	of	the	narrowest	site	of	the	torso	(minimal	
waist).	
Lohman	et	al.	(1988)	[20];	ISAK	
(2006)	[21]	
WC	2	 Measured	right	above	the	iliac	crest.	 NIH	 (1994)	 [22]	 CSEP	 (2010)	
[15]	
WC	3	 Measured	at	 the	mid-distance	between	the	 last	 rib	and	the	top	
of	the	iliac	crest.	
WHO	 (1987,	 2011)	 [23,	 41];	
Nishida	et	al.	(2010)	[8]	
WC	4	 Measured	at	the	level	of	the	umbilicus.	
Targher	 et	 al.	 (2008)	 [25];	
Rector	et	al.	(2011)	[24]		
WC	–	waist	circumference;	 ISAK	–	The	International	Society	for	the	Advancement	of	Kinanthropometry;	NIH	–	National	 Institute	of	Health;	CSEP	–	441 
Canadian	Society	of	Exercise	Physiology;	WHO	–	World	Health	Organization.	442 
	 	443 
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	Table	2.	Descriptive	data	of	the	studied	sample	of	patients	with	Non-Alcoholic	Fatty	Liver	Disease.	444 
 Patients with NAFLD (n=28) 
Variables Mean + sd *  Min. – Max. 
Age,	yr	(median,	yr)	 49.5	±	12.8	 (49)	 	 25	–	68	 	
Sex,	n	female	(%	female)		 9	 (32,1)	 	 	 	
Anthropometry	 	 	 	 	 	
Weight,	kg		 87.6	±	12.7	 	 	 66.2	–	115.8	 	
Stature,	cm		 167.2	±	9.2	 	 	 149.5	–	183.7	 	
BMI,	kg/m2	(%	obese)	 29.1	±	4.0	 (32.1)	 	 22.6	–	42.2	 	
WC	1,	cm		 100.7	±	8.2	 	 	 86.0	–	119.8	 	
WC	2,	cm		 104.8	±	10.6	 	 	 85.3	–	128.7	 	
WC	3,	cm		 103.7	±	10.4	 	 	 85.7	–	129.3	 	
WC	4,	cm		 106.3	±	11.5	 	 	 86.7	–	129.1	 	
Whole	and	Regional	Body	Composition	as	assessed	by	DXA	 	 	 	
BF,	kg	(%)	 27.2	±	9.3	 (31.31	±	8.20)	 	 13.7	–	51.2	 (18.84	–	46.28)	
FFM,	kg	(%)	 58.7	±	9.1	 (68.69	±	8.20)	 	 39.6	–	77.7	 (53.72	–	81.16)	
Trunk	BF,	kg	(%)	 15.2	±	5.2	 (33.15	±	7.65)	 	 7.4	–	25.0	 (20.87	–	48.01)	
Trunk	FFM	kg	(%)	 29.9	±	3.9	 (66.85	±	7.65)	 	 21.1	–	38.6	 (51.99	–79.13)	
Appendicular	BF,	kg	(%)	 10.8	±	4.8	 (30.42	±	10.39)	 	 5.2	–	25.7	 (13.63	–	50.40)	
Appendicular	FFM,	kg	(%)	 24.5	±	5.1	 (69.58	±	10.39)	 	 14.9	–	34.8	 (49.60	–	86.37)	
Abdominal	BF,	kg	(%)	 3.5	±	1.2	 (37.57	±	6.59)	 	 1.7	–	6.3	 (26.09	–	49.40)	
Central	Abdominal	BF,	kg	(%)	 2.9	±	0.8	 (35.82	±	5.70)	 	 1.6	–	5.0	 (24.28	–	44.64)	
BMI	–	body	mass	index;	WC1	–	Waist	circumference	as	measured	by	Lohman	et	al.	[20]	and	The	International	Society	for	the	Advancement	of	Kinanthropometry	(ISAK)	445 
[21];	WC2	-	Waist	circumference	as	measured	by	the	National	Institute	of	Health	(NIH)	from	the	United	States	of	America	[22];	WC3	-	Waist	circumference	as	measured	446 
by	the	World	Health	Organization	(WHO)	[41];	WC4	-	Waist	circumference	as	measured	by	Ross	et	al.,	Masson	et	al.,	Targher	et	al.	and	others	[7,	25,	36];	DXA	–	Dual-447 
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energy	X-ray	Absorptiometry;	BF	–	body	fat;	FFM	–	fat	free	mass;	*	Results	are	presented	as	mean	±	standard	deviation,	unless	otherwise	noted;	Min.	–	lowest	observed	448 
value;	Máx.	–	highest	observed	value	449 
	450 
	451 
Table	 3.	 Mean	 differences	 and	 P	 values	 from	 paired	 samples	 T	 test	 used	 in	 the	452 
comparison	 between	 waist	 circumference	 results	 obtained	 with	 different	453 
measurement	protocols,	in	28	patients	with	NAFLD		454 
Variables	 WC	1,	cm	 	 	 WC	2,	cm	 	 	 WC	3,	cm	 	
	 Dif	†	 p	 	 Dif	†	 p	 	 Dif	†	 p	
WC2	 4,1	 0.000	 	 --	 --	 	 --	 --	
WC3	 3,0	 0.000		 	 -1,1	 0.000	 	 --	 --	
WC4	 5.6	 0.000	 	 1,5	 0.012	 	 2,6	 0.001	
NAFLD	 –	 Non-Alcoholic	 Fatty	 Liver	 Disease;	 WC1	 –	 Waist	 circumference	 measured	 minimal	 waist;	 WC2	 -	 Waist	455 
circumference	measured	 just	 above	 iliac	 crest;	WC3	 -	Waist	 circumference	measured	 at	mid-distance;	WC4	 -	Waist	456 
circumference	 measured	 at	 the	 umbilicus;	 †	 -	 difference	 between	 results	 obtained	 using	WC	 protocols	 in	 the	 Left	457 
column	and	the	results	from	the	WC	protocols	in	the	top	line.		458 
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	459 
Table	4.	Partial	and	semipartial	correlations	between	waist	circumferences,	obtained	using	different	460 
measurement	protocols,	and	the	studied	body	fat	depots,	in	28	patients	with	NAFLD.	461 
	 WC	1,	cm	 	 	 WC	2,	cm	 	 	 WC	3,	cm	 	 	 WC	4,	cm	 	
Variables	 r	†	 r	‡	 	 r	†	 r	‡	 	 r	†	 r	‡	 	 r	†	 r	‡	
BF,	kg	 0.63*	 0.34	 	 0.68**	 0.37	 	 0.66*	 0.36	 	 0.77**	 0.35	
BF,	%	 0.46	 0.23		 	 0.45	 0.22	 	 0.46	 0.22	 	 0.54*	 0.28	
Trunk	BF,	kg	 0.78**	 0.52**	 	 0.82**	 0.54**	 	 0.82**	 0.54**	 	 0.84**	 0.51**	
Trunk	BF,	%	 0.56*	 0.35	 	 0.54*	 0.34	 	 0.56*	 0.34	 	 0.57*	 0.30	
Abdominal	BF,	kg	 0.78**	 0.68**	 	 0.78**	 0.69**	 	 0.80**	 0.70**	 	 0.72**	 0.66**	
Abdominal	BF,	%	 0.59*	 0.49	 	 0.57*	 0.47	 	 0.58*	 0.48	 	 0.47	 0.44	
Central	Abd	BF,	kg	 0.76**	 0.73**	 	 0.77**	 0.74**	 	 0.78**	 0.75**	 	 0.68**	 0.70**	
Central	Abd	BF,	%	 0.52*	 0.48	 	 0.53*	 0.46	 	 0.54*	 0.47	 	 0.48	 0.44	
NAFLD	–	Non-Alcoholic	Fatty	Liver	Disease;	WC1	–	Waist	circumference	measured	minimal	waist;	WC2	-	Waist	circumference	measured	just	above	462 
iliac	crest;	WC3	-	Waist	circumference	measured	at	mid-distance;	WC4	-	Waist	circumference	measured	at	the	umbilicus;	BF	–	body	fat;	Central	Abd	463 
BF	–	Central	abdominal	body	fat;	†	-	partial	correlations	between	studied	circumferences	and	dependent	variables,	controlled	for	age,	sex	and	body	464 
mass	 index;	‡	-	semipartial	correlations	between	studied	circumferences	and	dependent	variables,	removing	the	effect	of	age,	sex	and	body	mass	465 
index;	*	-	significant	for	p<0,01;	**	-	significant	for	p<0,001.	466 
	 	 	467 
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Table	 5.	 Z	 statistic	 P	 values	 for	 the	 comparison	 between	 the	 coefficients	 of	 correlation	 found	 in	 partial	 and	468 
semipartial	 correlations	 between	waist	 circumferences,	 obtained	 using	 different	measurement	 protocols,	 and	469 
the	absolute	(lower-left	half	of	table)	and	relative	(upper-right	half	of	the	table)	results	for	DXA	assessed	body	fat	470 
depots	in	28	patients	with	NAFLD.		471 
	 	 WC1	 	 	 WC2	 	 	 WC3	 	 	 WC4	 	 	 	
Variablesa	
	 p†	 p‡	 	 p†	 p‡	 	 p†	 p‡	 	 p†	 p‡	 	 Variablesb	
	 	 	 	 	 0.954	 0.982	 	 0.971	 0.988	 	 0.874	 0.841	 %BF	 WC1	
	 	 Blank	separator	 	 0.923	 0.962	 	 0.980	 0.990	 	 0.715	 0.853	 Trunk	%BF	 	
	 	 Data	do	 not	apply		 	 0.886	 0.920	 	 0.949	 0.963	 	 0.747	 0.836	 Abd	%BF	 	
	 	 	 	 	 0.909	 0.928	 	 0.952	 0.964	 	 0.836	 0.865	 C	Abd	%BF	 	
WC2	 BF	 0.744	 0.907	 	 	 	 	 0.982	 0.994	 	 0.920	 0.824	 %BF	 WC2	
	 Trunk	BF	 0.754	 0.918	 	 	 	 	 0.944	 0.971	 	 0.788	 0.828	 Trunk	%BF	 	
	 Abd	BF	 0.950	 0.968	 	 	 	 	 0.937	 0.957	 	 0.899	 0.915	 Abd	%BF	 	
	 C	Abd	BF	 0.912	 0.921	 	 	 	 	 0.957	 0.964	 	 0.927	 0.936	 C	Abd	%BF	 	
WC3	 BF	 0.828	 0.939	 	 0.913	 0.968	 	 	 	 	 0.902	 0.830	 %BF	 WC3	
	 Trunk	BF	 0.746	 0.918	 	 0.992	 1.000	 	 	 	 	 0.734	 0.862	 Trunk	%BF	 	
	 Abd	BF	 0.799	 0.876	 	 0.848	 0.908	 	 	 	 	 0.837	 0.872	 Abd	%BF	 	
	 C	Abd	BF	 0.842	 0.864	 	 0.929	 0.943	 	 	 	 	 0.884	 0.901	 C	Abd	%BF	 	
WC4	 BF	 0.881	 0.958	 	 0.859	 0.948	 	 0.946	 0.981	 	 	 	 	 	
	 Trunk	BF	 0.881	 0.958	 	 0.643	 0.876	 	 0.635	 0.876	 	 	 	 	 	
	 Abd	BF	 0.819	 0.879	 	 0.770	 0.985	 	 0.629	 0.758	 	 	 	 	 	
	 C	Abd	BF	 0.849	 0.862	 	 0.763	 0.784	 	 0.697	 0.730	 	 	 	 	 	
DXA	–	Dual-energy	X-ray	Absorptiometry;	NAFLD	–	Non-Alcoholic	Fatty	Liver	Disease;	
a
	–	Variables	in	the	left	column	apply	to	the	lower-left	half	of	the	table:	
b
	472 
–	Variables	 in	 the	 right	 column	apply	 to	 the	upper-right	half	of	 the	 tale;	WC1	–	Waist	 circumference	measured	minimal	waist;	WC2	 -	Waist	 circumference	473 
measured	just	above	iliac	crest;	WC3	-	Waist	circumference	measured	at	mid-distance;	WC4	-	Waist	circumference	measured	at	the	umbilicus;	†	-	comparison	474 
between	correlation	coefficients	obtained	in	partial	correlations	between	waist	circumferences	and	all	dependent	variables,	controlled	for	age,	sex	and	BMI;	‡	-	475 
comparison	between	correlation	 coefficients	obtained	 in	 semipartial	 correlations	between	waist	 circumferences	and	all	 dependent	 variables,	 removing	 the	476 
effect	of	age,	sex	and	BMI.	477 
	478 
	 	479 
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Table	 6.	 Coefficient	 of	 variation	 and	 time	 length	 for	480 
measurement	of	each	waist	circumference	protocol.	481 
VARIABLES	 WC	1	 	 WC	2	 	 WC	3	 	 WC	4	
COV	 0.045	 	 0.049	 	 0.047	 	 0.073	
TLM,	sec.	 35±6*	 	 44±4**	 	 74±4**	 	 34±5***	
COV	 –	 mean	 coefficient	 of	 variation,	 TLM	 –	 mean±standard	 deviation	 of	 time	 length	 of	482 
measurements,	in	seconds;	WC1	–	Waist	circumference	measured	minimal	waist;	WC2	-	Waist	483 
circumference	measured	 just	 above	 iliac	 crest;	WC3	 -	Waist	 circumference	measured	 at	mid-484 
distance;	WC4	 -	Waist	 circumference	measured	at	 the	umbilicus;	 *	 -	 different	 from	WC2	and	485 
WC3	(p<0-001)	but	not	WC4	(P=0.522);	**	-	different	from	all	other	WC	TLM	(p<0.001);	***	-	-	486 
different	from	WC2	and	WC3	(p<0-001)	but	not	WC1	(P=0.522).		487 
488 
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FIGURE	LEGENDS:	489 
	490 
Figure	1	-	Image	of	a	DXA	scan	showing	the	abdominal	region	of	interest	defined	as	the	area	491 
within	the	upper	edge	of	the	second	lumbar	vertebra	and	de	lower	edge	of	the	fourth	492 
lumbar	vertebra.	493 
	494 
Figure	2	-	Representation	of	waist	circumference	measuring	sites	over	a	DXA	scan	image.	495 
WC1	–	waist	circumference	measured	at	minimal	waist;	WC2	-	waist	circumference	496 
measured	just	above	iliac	crest;	WC3	–	waist	circumference	measured	at	mid-distance	497 
between	lowest	rib	and	iliac	crest;	WC4	–	waist	circumference	measured	at	the	umbilicus. 498 
	499 
